Clarification of drug sensitivity in leukemia cells by comprehensive analysis by microarray technology
| Project/Area Number |
15K19609
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 薬剤反応性 / がん / 遺伝子 / マイクロアレイ |
|---|
| Outline of Final Research Achievements |
Decitabine, a DNA demethylating agent, showed improved drug sensitivity in acute lymphocytic leukemia cell lines, CCRF-CEM, Jurkat, BALL-1, and NALM-6. Three genes, MEST, NDRG4, and ZNF750, are known as tumor suppressor genes, and observed DNA demethylation and increase in mRNA expression level by the addition of decitabine. Therefore, we considered these genes are the candidate genes concerning drug sensitivity in leukemia cells. However, further study was required to whether these genes are truly concerning drug sensitivity.
|
Report
(4 results)
Research Products
(1 results)
